Core Viewpoint - Teladoc Health, Inc. is under investigation for potential securities law violations following a report from Blue Orca Capital, which alleges misleading practices regarding its BetterHelp platform and financial reporting [2][4]. Group 1: Investigation Details - Block & Leviton is investigating Teladoc Health for possible securities law violations and may file an action to recover losses for affected investors [4]. - The investigation was prompted by a report claiming that BetterHelp utilized AI-generated responses instead of licensed therapists without proper disclosures [2]. - The report also accuses Teladoc of inflating profitability by shifting research and development expenses [2]. Group 2: Investor Eligibility - Any investor who purchased Teladoc Health common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their investment [3]. Group 3: Whistleblower Information - Individuals with non-public information about Teladoc Health are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Group 1 - Teladoc (NYSE: TDOC) experienced significant positive momentum over the past three months, largely driven by investor optimism and speculation regarding its potential in the AI sector [1] - The narrative surrounding Teladoc's overlooked AI capabilities gained traction following the company's recent announcements [1] Group 2 - The article emphasizes the importance of data analytics in identifying investment opportunities within the equity markets, highlighting the vast amount of data available from SEC filings and other sources [1]

Core Viewpoint - Citron Research identifies Teladoc Health as a hidden opportunity in the AI sector within telemedicine, despite its current perception as a "pandemic relic" [2][5]. Company Performance - Teladoc's stock peaked at nearly $300 during the COVID-19 pandemic but has since dropped significantly, trading at 95% below its all-time highs as of February 10 [3][9]. - The company experienced a surge in demand for telemedicine services during the pandemic, which has since slowed down post-economic reopening [4][5]. Financial Metrics - While revenue growth has plateaued, Teladoc's free cash flow has been increasing, indicating improved operational efficiencies and higher profit margins [6][5]. - Citron suggests that Teladoc's current valuation appears attractive on a price-to-free-cash-flow basis, despite the stock being perceived as oversold [9]. Technology and AI Integration - Citron claims that Teladoc is effectively utilizing technology, although the company did not mention "artificial intelligence" during its recent earnings call, indicating that AI may not be a priority [8][10]. - The potential for Teladoc to be an acquisition target for larger companies like Amazon or CVS Health is highlighted, although this remains speculative [8][10]. Investment Outlook - Despite the positive aspects noted by Citron, there is skepticism regarding the narratives of Teladoc being a hidden AI gem or a likely acquisition candidate, suggesting that the stock may not be a solid buy at this time [11].

Company Overview - Teladoc Health shares increased by 8.8% in the last trading session, closing at $11.97, with notable trading volume compared to typical sessions [1] - The stock has gained 12.5% over the past four weeks, indicating positive momentum [1] Recent Developments - The recent rally in Teladoc's stock is attributed to optimism surrounding its acquisition of Catapult Health and endorsement from Citron Research, which labeled it an "Under-the-Radar AI Play" [2] - The company is focusing on strategic technology investments, particularly in AI, to enhance profitability [2] Financial Expectations - Teladoc is expected to report a quarterly loss of $0.21 per share, reflecting a year-over-year decline of 23.5% [3] - Revenue projections stand at $639.5 million, which is a decrease of 3.2% compared to the same quarter last year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for Teladoc has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - Historical trends indicate that stock prices typically do not continue to rise without changes in earnings estimate revisions, highlighting the importance of monitoring Teladoc's performance moving forward [4] Industry Context - Teladoc is part of the Zacks Medical Services industry, which includes other companies like Sonida Senior Living [4] - Sonida Senior Living has a consensus EPS estimate of -$0.71 for its upcoming report, representing a 67.3% improvement from the previous year [5]

Shares of telemedicine company Teladoc Health (TDOC 8.82%) surprisingly popped on Thursday after Citron Research gave it a glowing recommendation. As of 3:30 p.m. ET, Teladoc stock was up 7%, but it had been up as much as 15% earlier in the day.Is this a sudden cash-flow opportunity?Teladoc stock has been completely discarded by investors. A stock market darling in 2020, it's dropped 96% from its all-time high in early 2021. This is why the shoutout from Citron Research was so surprising. The research firm ...

Virtual care company Teladoc Health is bolstering its at-home diagnostics capabilities by acquiring Catapult Health.The $65 million deal is designed to support Teladoc’s efforts to improve early detection of health conditions, according to a Wednesday (Feb. 5) press release.“Catapult Health’s capabilities will help advance our strategy in meaningful ways — from giving more members access to convenient and impactful wellness and preventative care, to unlocking greater value for our customers,” Teladoc CEO Ch ...

Teladoc Health on Wednesday announced it will acquire the preventative care company Catapult Health in an all-cash deal for $65 million.Catapult offers an at-home wellness exam that allows members to check their blood pressure, collect a blood sample, log other screening information and meet virtually with a nurse practitioner. Teladoc, a virtual care platform, said the acquisition will help it improve its ability to detect health conditions early.The company said Catapult will operate within its integrated ...

Strategic acquisition will enhance Teladoc Health’s preventive care and chronic care management capabilities, expand at-home testing VirtualCheckup With Catapult Health’s innovative at-home wellness exam, VirtualCheckup, members receive a simple kit with everything they need to collect a blood sample, check blood pressure, and provide other health screening information, followed by a virtual visit with a licensed nurse practitioner to discuss test results, review key health risks, and create a personalize ...

PURCHASE, NY, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release fourth quarter 2024 results on Wednesday, February 26, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 259200. For international participan ...

Teladoc (TDOC) closed at $9.09 in the latest trading session, marking a -0.76% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1%. Meanwhile, the Dow gained 0.78%, and the Nasdaq, a tech-heavy index, added 1.51%.Prior to today's trading, shares of the telehealth services provider had gained 2.12% over the past month. This has outpaced the Medical sector's loss of 1.36% and the S&P 500's loss of 2.14% in that time.The investment community will be paying close attentio ...